Breast cancer
Conditions
Interventions
None listed
Sponsors
Erasmus Medisch Centrum
Eligibility
Inclusion criteria
Inclusion criteria: - Breast cancer patients with local recurrent or distant metastases - The site of the tumor should be easy amendable for biopsy. NB: lung metastases (high risk of hematothorax) and bone metastases (not suitable for ex vivo HRD test because calcifications interfere with experimental procedures) are excluded. - Age >18 years - WHO performance status 0 or 1 - Bilirubin 100 x 10e9/L and INR <1.5, unless platelet/INR values are not necessary according to local protocols or after consent of the intervention radiologist for that particular site of biopsy (e.g. biopsy of the skin). - Written informed consent
Exclusion criteria
Exclusion criteria: - Current therapeutically use of anti-coagulant (coumarin derivates, warfarin, heparin or low molecular weight heparin [LMWH]) whereby a short interruption of drug use is not allowed. LMWH if used for prophylaxis is allowed. Use of low molecular weight heparin (LMWH) should be interrupted shortly before biopsy is scheduled, unless this is not necessary according to local protocols or after consent of the intervention radiologist. - Any psychological condition potentially hampering compliance with the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of biopsies from local recurrent or metastatic lesions showing HRD among patients with BR grade 3 ER/PR+ or HER2+ breast cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| - The percentage of biopsies from local recurrent or metastatic lesions showing HRD among the BR grade 3 ER/PR+ subgroup alone. - The percentage of biopsies from local recurrent or metastatic lesions showing HRD among patients with BR grade grade 1/2 ER/PR+ breast cancers and TNBC. | — |
Contacts
Public ContactA. Jager
Erasmus MC, Room 471
Outcome results
None listed